ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
Ariana Huebner(The Francis Crick Institute), Rodrigo A. Toledo(Instituto de Salud Carlos III), James R. Black(Cancer Research UK), Ana Belén Moreno-Cárdenas(Vall d'Hebron Hospital Universitari), Francesca Sarno, Laura Medina(Instituto de Investigación Biomédica de Málaga), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Carmen Guillén‐Ponce(Hospital Universitario Ramón y Cajal), Helena Verdaguer(Vall d'Hebron Institut de Recerca), Nicholas McGranahan(CRUK Lung Cancer Centre of Excellence), Roberto Pazo(Hospital Universitario Miguel Servet), Carolina Alonso, Teresa Macarulla(Vall d'Hebron Hospital Universitari), Manuel Hidalgo(Hospital Universitario de Fuenlabrada), Jaime Feliú(Hospital Universitario La Paz), Carlota Arenillas(Universitat Autònoma de Barcelona), Ignacio Juez(Hospital Universitario de Fuenlabrada)
Cited by 8
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k